Virtual Library
Start Your Search
Bo Shen
Author of
-
+
P48 - Small Cell Lung Cancer/NET - Chemo - IO (ID 236)
- Event: WCLC 2020
- Type: Posters
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P48.24 - Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (ID 3826)
00:00 - 00:00 | Presenting Author(s): Bo Shen
- Abstract
Introduction
Existing maintenance treatment strategies for patients with extensive-stage small cell lung cancer (ES-SCLC) experiencing no progression after the standard first-line chemotherapy are limited. Previous analysis in ALTER1202 showed anlotinib, a novel oral multitarget tyrosine kinase inhibitor, significantly prolonged progression-free survival (PFS) and overall survival (OS) in relapsed SCLC who failed ≥ 2 lines of chemotherapy. The aim of this study was to assess the efficacy and safety of anlotinib combined with etoposide as maintenance treatment in patients with ES-SCLC after the standard first-line EP chemotherapy.
Methods
Patients with histologically confirmed ES-SCLC who have not progressed after the standard first-line EP chemotherapy received anlotinib (12 mg, QD, from day 1 to 14, every 3 weeks) combined with etoposide (50 mg, QD, day 1 to 14 of a 21-day cycle, up to 6 cycles) until disease progression or unacceptable toxicity. The primary endpoint was PFS. Secondary endpoints were OS and safety. The study was registered at Chinese Clinical Trial Registry (ChiCTR1800019421).
Results
Between April 2019 and August 2020, we screened 18 patients and enrolled 16 patients in this trial. At data cut-off (August 1, 2020), 10 (62.5%) patients had discontinued the study, and 6 (27.5%) patients remained on treatment. Among the 16 patients, 15 patients were evaluated for efficacy. 4 patients reached partial response (PR) and 10 had stable disease (SD). The median PFS (mPFS) was 8.7 month (95%CI: 3.7-9.1). The objective response rate (ORR) and the disease control rate (DCR) were 26.7% and 93.3%, respectively. The most common grade 1-2 adverse events (AEs) included anorexia (9 of 16, 56.3%), hypertension (9 of 16, 56.3%) and fatigue (6 of 16, 37.5%). The grade 3 AEs were anorexia (2 of 16, 12.5%), hypertension (1 of 16, 6.25%).
Conclusion
The combination of anlotinib and etoposide appeared to have significant efficacy and favorable safety profile as maintenance treatment in patients with ES-SCLC having not progressed after the standard first-line EP chemotherapy. The further exploration is ongoing.